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Background: The aim of the present study was to examine the postprandial calcium and phosphate
concentrations after supplementation with pentacalcium hydroxy-triphosphate (CaP).
Methods: Ten men participated in this double-blind, placebo-controlled, cross-over study. The participants were
divided into two groups. One group consumed bread enriched with CaP (plus 1 g calcium/d) and the other group
a placebo product for three weeks. After a two week wash-out, the intervention was switched between the groups
for another three weeks. Blood samples were drawn at the beginning (single administration) and at the end
(repeated administration) of the intervention periods at 0, 30, 60, 120, 180 and 240 min. Between 0 and 30 min, a
test meal, with or without CaP was consumed. The plasma concentrations of calcium and phosphate were
examined. One participant dropped out due to personal reasons.
Results: CaP supplementation resulted in a significantly higher plasma calcium concentration after 240 min
compared to placebo. After repeated CaP administration, the AUC for the increment in plasma calcium
concentration was significantly higher compared to placebo.
After single and repeated CaP supplementation, plasma phosphate concentration significantly decreased after 30,
60, 120 and 180 min compared to 0 min. The placebo administration resulted in significant decreases after 30, 60
and 120 min compared to 0 min.
Conclusion: Our results show that CaP contributes to an adequate calcium supply, but without increasing the
plasma concentration of phosphate.
Trial registration: www.clinicaltrials.gov; NCT01296997
Keywords: Calcium phosphate, Plasma calcium, Plasma phosphate, Human studyBackground
Hyperphosphatemia is recognized as a risk factor for
mortality in chronic kidney disease [1]. In addition,
serum phosphate concentration within the upper limits
of normal is associated with a greater prevalence of vas-
cular and valvular calcification in patients with moderate
chronic kidney disease [2]. In the last years, our research
group performed human studies involving calcium* Correspondence: b6jage@uni-jena.de
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distribution, and reproduction in any mediumphosphate supplementation [3-5]. Most studies with
calcium phosphate focus on the beneficial effects relating
to intestinal metabolism, e.g. bile acid metabolism, fatty
acid excretion, and modulation of the microbiota [5-8].
This is because amorphous calcium phosphate is formed
in the human gut and, moreover, is able to precipitate
intestinal substances, such as bile or fatty acids [6,7,9].
However, calcium phosphate is poorly absorbed in the
gut. Evidence comes from studies showing unchanged
fasting plasma concentrations of calcium and phosphate
after calcium phosphate supplementation [4]. Neverthe-
less, measuring fasting concentrations is not a convincingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Study flowchart. CaP: pentacalcium hydroxy-triphosphate.
Figure 2 Design of the double-blind, placebo-controlled
cross-over study. wk: week; CaP: pentacalcium hydroxy-
triphosphate; blood: blood sampling at time points 0, 30, 60, 120,
180 and 240 minutes; between 0 and 30 minutes, the participants
consumed a test meal with or without CaP; DD: defined diet for
three days before blood sampling.
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supplementation on calcium and phosphate status.
Furthermore, Heaney et al. showed that solubility of a
calcium supplement has very little influence on its
absorbability and that absorption of calcium from food
sources is determined mainly by other food components
[10]. In addition, it is necessary to test every calcium prod-
uct for absorbability [11]. Therefore, in this human study,
we examined the postprandial calcium and phosphate
concentrations after calcium phosphate supplementation of
both a single dose and after three weeks.
Methods
Supplement
For purposes of supplementation, we used pentacalcium
hydroxy-triphosphate (Ca5(PO4)3OH; cfb; Budenheim
Germany; CaP) in this study. CaP was incorporated in
whole wheat bread to achieve an additional calcium
intake of 1 g/d (0.5 g phosphorus/d). Participants
consumed approximately 135 g of this bread daily. Placebo
bread was prepared in exactly the same way, but without
the CaP supplement.
Subjects
The study was conducted between July and September
2010 in the Institute of Nutrition, Department of
Nutritional Physiology at the Friedrich Schiller University
Jena. Ten omnivorous men participated in this double-
blind, placebo-controlled, cross-over study. Eligibility
criteria for participants included age between 20 and
35 years and good physical health. A further criterion
was that participants remain at the blood withdrawal
centre for at least 5 hours between 7.30 am till 12.30 pm.
Volunteers were provided with detailed information
regarding purpose, course, and possible risks involved in
the study. All participants gave their written informed
consent. The study protocol was approved by the Ethical
Committee of the Friedrich Schiller University, Jena
(No.:2833-05/10). Of the initial ten volunteers, one
participant dropped out due to personal reasons. The
main study outcomes comprised blood concentrations
of calcium and phosphate (Figure 1).
Study design
Participants were divided into two groups. For a period
of three weeks, one group consumed bread containing
CaP whereas the other group consumed the placebo
product. This was followed by a two-week wash-out
phase. Thereafter, the intervention changed between the
two groups for a further three weeks. Thus, the study
design allowed that every participant was his own
control. The intervention periods are divided in two
parts. At the beginning the participants ate the test
bread with or without CaP onetime and then blood wastaken (single administration). Afterwards the participants
consumed the test bread three weeks daily and then blood
was taken again (repeated administration). Consequently,
the study involved four types of administrations: single CaP
administration, single placebo administration, repeated CaP
administration and repeated placebo administration. In
addition, participants consumed a defined diet for three
days before each blood sample was taken (Figure 2).
The defined diet containing the complete food supply
for three days was prepared and pre-weighed in the
study centre. The subjects were instructed to consume
no other foods than provided. Any food residues were
weighed and food intake was calculated.
On the day of blood withdrawal, participants came
fasting to the Institute of Transfusion Medicine of the
Jena University Hospital. Blood samples were drawn
Table 1 Baseline characteristics of participants who
completed the study
Subject (n= 9)
Age [y] 27 ± 4
Height [cm] 178 ± 5
Weight [kg] 73.2 ± 7.5
BMI [kg/m2] 23.1 ± 2.3
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cooled, and transported to the study centre.
Between time point 0 and 30 minutes, the participants
consumed a test meal. The test meal consisted of bread
with or without CaP (according to the intervention),
20 g butter, 25 g ham, 15 g sweet hazelnut spread and a
banana. During the 240 min the participants were
allowed to drink water ad libitum.
Sample preparation
Samples of each food component of the defined diet
were frozen and stored at −20°C until analysis. Blood
was collected in lithium heparin tubes. Plasma was
obtained by centrifugation at 2500 x g for 15 minutes at
20°C. Aliquots were frozen at −80°C until analysis.
Food analysis
The intake of energy, fat, proteins, and carbohydrates was
verified using the ProdiW 5.4 software (Nutri-Science
GmbH, Freiburg, Germany). For intake of minerals, the
respective contents in the provided foods were analysed
instead of using the calculation software. Mineral contents
of all food samples were determined employing the iCAP
6000 ICP Spectrometer (Thermo Scientific, Waltham,
USA). Before analysis, the samples were ashed at 525°C.
The ash was dissolved in HCl (25%) and diluted with
distilled water.
Analysis of calcium and phosphate
Calcium and phosphate in plasma were quantified using the
autoanalyser ARCHITECT C16000 (Abbott, Illinois, USA)
according to the manufacturer’s recommendations.
Calculations and statistical methods
Samples from each participant were coded to protect
volunteer identity and to mask treatment groups during
the analysis. The areas under the curves (AUC) from 0
to 240 min were calculated using the trapezoidal
method. The calculation based on the increment in
plasma calcium and phosphate concentrations.
All values in the text and tables were expressed as
mean ± standard deviation. For reasons of clarity and
comprehensibility, values in figures were expressed only as
means. Data analysis was performed using the statistical
software package PASW Statistics 18 (SPSS Inc., Chicago,
USA). Differences were considered significant at p ≤ 0.05.
The effect of time was tested only to baseline using paired
Student’s t-test. The effect of supplementation was tested
with paired Student’s t-test. The sample size for calcium
and phosphate was n = 9.
Results
Nine subjects completed the four blood samples and test
meals. The baseline characteristics and the nutrientintake of the test meal and defined diet are presented in
Tables 1 and 2.
The calcium and phosphorous concentrations of the
CaP bread was 1129 mg/135 g bread and 749 mg/135 g
bread, respectively. The placebo bread contained 26 mg
calcium/135 g bread and 229 mg phosphorus/135 g
bread, respectively.
Following single administration with CaP, calcium
concentration increased significantly after 120 (p = 0.043)
and 240 min (p ≤ 0.001) compared to 0 min. The three
week administration of CaP led to an increase of calcium
concentration after 60 (p = 0.026), 180 (p = 0.011) and 240
(p = 0.001) min compared to 0 min (Figure 3). Both the
single and the repeated administration of CaP resulted in
a significantly higher calcium concentration after 240 min
(p = 0.005, p = 0.006) compared to placebo. After repeated
administration, the AUC for the increment in calcium con-
centration was significantly higher after CaP administration
compared to placebo (p = 0.007).
After single and repeated CaP supplementation, the
phosphate concentration significantly decreased after 30
(single: p ≤ 0.001, repeated: p = 0.002), 60 (single: p ≤ 0.001;
repeated: p ≤ 0.001), 120 (single: p = 0.006, repeated:
p = 0.006) and 180 (single: p = 0.043, repeated: p = 0.041)
min compared to 0 min. The placebo administration
resulted in similar significant decreases after 30 (single:
p ≤ 0.001; repeated: p = 0.001), 60 (single: p ≤ 0.001;
repeated: p ≤ 0.001) and 120 (single: p = 0.007; repeated:
p = 0.011) min compared to 0 min.
Following single CaP and placebo administration, the
calcium-phosphorus product significantly decreased
compared to 0 (CaP: 2.5 mmol2/l2; placebo: 2.6 mmol2/l2)
after 30 (CaP: 2.3 mmol2/l2, p ≤ 0.001; placebo: 2.3 mmol2/l2,
p = 0.003), 60 (CaP: 2.1 mmol2/l2, p ≤ 0.001; placebo:
2.1 mmol2/l2, p ≤ 0.001), 120 (CaP: 2.1 mmol2/l2, p = 0.006;
placebo: 2.2 mmol2/l2, p = 0.008) and 180 (CaP: 2.3 mmol2/l2,
p = 0.049; placebo: 2.3 mmol2/l2, p = 0.031) min, respectively.
After repeated CaP and placebo administration, the
calcium-phosphorus product significantly decreased after
30 (CaP: 2.4 mmol2/l2, p = 0.001; placebo: 2.4 mmol2/l2,
p = 0.001), 60 (CaP: 2.1 mmol2/l2, p = 0.001; placebo:
2.2 mmol2/l2, p ≤ 0.001) and 120 (CaP: 2.1 mmol2/l2,
p = 0.011; placebo: 2.2 mmol2/l2, p = 0.012) min compared
to 0 min (CaP: 2.6 mmol2/l2, placebo: 2.6 mmol2/l2). At
Table 2 Mean nutrient composition of the test meal and
the defined diet
Test meal (per meal) Defined (per day)
Energy [MJ] 2,6 ± 0,1 10,4 ± 1,4
Carbohydrates [g] 82,1 ± 3,4 292,9 ± 41,2
Fat [g] 23,5 ± 0,1 101,6 ± 19,1
Protein [g] 16,7 ± 0,3 85,3 ± 6,3
CaP Placebo CaP Placebo
Ca [mg] 1160 ± 1 55 ± 1 2019 ± 75,2 926 ± 57
from CaP [mg] 1104 0 1104 0
P [mg] 868 ± 4 346 ± 5 2050 ± 127 1542 ± 104
from CaP [mg] 519 0 519 0
N = 9; data are expressed as mean ± standard deviation; CaP pentacalcium
hydroxy-triphosphate, Ca calcium, P phosphorus.
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higher after CaP administration compared to placebo
administration (p = 0.031).
Discussion
Calcium has a tightly regulated homeostasis rendering it
unsuitable for comparing fasting calcium concentrations for
the purpose of determining the effect of supplementationFigure 3 Mean plasma calcium and phosphate concentrations and ar
plasma calcium and phosphate after single and repeated administrat
are expressed as mean ± standard deviation;▲ significant differences to 0 m
supplementation;Δ significant differences to 0 min after placebo administr
administration (p ≤ 0.05); the effects of time and of supplementation were
triphosphate; AUC: area under the curve.on calcium status. Although, there are some studies in
the literature in which the calcium concentration was
determined following a short time interval after calcium
intake [12-16]. For instance, Heaney et al. compared the
bioavailability of calcium from two fortification systems. A
combination of tricalcium phosphate and calcium lactate
(500 mg calcium, orange juice) led to an increase in serum
calcium of almost 0.35 mg/dl (0.09 mmol/l) after two
hours [14]. In the study of Green et al., the change in
the calcium concentration after tricalcium phosphate
(1200 mg calcium, powder mixed in water) was 0.1 mmol/l
[12]. In present study, plasma calcium concentration rose
by approximately 0.06 mmol/l in four hours after single
administration and by about 0.1 mmol/l after repeated
administration. The significantly higher calcium concentra-
tion at 240 min after single and repeated CaP administra-
tion and the significantly higher AUC for the increment in
calcium concentration after repeated CaP administration
compared to placebo suggest that part of the calcium from
the CaP supplement was absorbed. Supplementation with
CaP led to an increase in blood calcium concentration,
which is comparable to other studies.
Because hyperphosphatemia is linked with vascular
calcification, cardiovascular mortality, and progression
of chronic kidney disease, phosphate intake is an aspectea under the curve from 0 to 240 min for the increment in
ion of CaP. N = 9; data are expressed as means, areas under the curve
in after CaP supplementation (p ≤ 0.05); ○ placebo; ● CaP
ation (p ≤ 0.05); * significant differences between CaP and placebo
tested with paired Student’s t-test; CaP: pentacalcium hydroxy-
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study, there was no difference in the plasma phosphate
concentration between CaP and placebo after 240 min.
In another study by Reginster et al. comprising 10 male
subjects, the serum phosphorus concentration did not
change after supplementation with tricalcium phosphate
(1000 mg Ca) within a time frame of 360 min [20]. In
contrast, both Yang et al. and Shires et al. showed an
increase in phosphorus concentration after an intake of
1200 mg calcium [21,22].
Interestingly, after all administrations (single CaP
and placebo administration, repeated CaP and placebo
administrations), phosphate concentration significantly
decreased at first, followed by a rise to basal concentration
(Figure 2). Karp et al. showed similar results for plasma
phosphate concentration after supplementation with
different calcium supplements and potassium citrate
[23]. Because of a decrease in bone resorption, the authors
assumed a decrease in the release of phosphate from
bone for potassium citrate only [23]. Moreover,
hypophosphatemia can be a result of phosphate shifts
from the blood into the cells, such as after ingestion of
glucose, fructose, and feeding following starvation
(phosphorylation processes) [24]. A glucose load can
induce a transient reduction in serum phosphate levels
[24], probably due to secretion of gastrointestinal
hormones and subsequent stimulation of calcitonin
[25]. Calcitonin induces an inhibition of osteoclasts and
a reduction in the release of phosphorus from bone into
blood. However, the association between gastrointestinal
hormones and calcitonin has only been shown in rodents
and not in humans [26].
Alternatively, the decreasing concentration of phosphate
in the present study can also be explained by a dilution ef-
fect as participants were allowed to drink water ad libitum
after the test meal. Between time points 60–120 min, the
phosphate concentration increased again to baseline levels
indicating that intestinal phosphate absorption took place
within this time frame. Indeed, in the study by Karp et al.,
the participants were also allowed to drink water ad libitum
[23]. In contrast, studies in which liquid intake were
restricted showed either an immediate increase or a
constant phosphate concentration [20-22].
Hence, the present results indicate that the increased
phosphate intake due to the CaP supplementation, did
probably not lead to an increased phosphate absorption
in the gut. This conclusion is supported by comparably
postprandial phosphate concentrations and the similar
AUC for the increment in phosphate concentration after
CaP and placebo administrations. In order to confirm
these results, isotopic tracer studies are indicated.
However, the results show that phosphate from this
CaP supplement did not lead to an increase in plasma
phosphate concentration.Conclusion
In conclusion, our results show that CaP contributes to
an adequate calcium supply, but without increasing the
plasma concentration of phosphate. Indeed, the major
part of the phosphate from the CaP supplement is
precipitated as amorphous calcium phosphate in the
human gut, an aspect that has been shown in several
human studies [3,5,27,28].
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